CO6351711A2 - Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina - Google Patents

Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina

Info

Publication number
CO6351711A2
CO6351711A2 CO11036957A CO11036957A CO6351711A2 CO 6351711 A2 CO6351711 A2 CO 6351711A2 CO 11036957 A CO11036957 A CO 11036957A CO 11036957 A CO11036957 A CO 11036957A CO 6351711 A2 CO6351711 A2 CO 6351711A2
Authority
CO
Colombia
Prior art keywords
alisquirene
amlodipine
percent
minutes
single layer
Prior art date
Application number
CO11036957A
Other languages
English (en)
Inventor
Stephen Valazza
Robert Wagner
Sudha Vippagunta
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42040192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6351711(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6351711A2 publication Critical patent/CO6351711A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de dosis oral fija, la cual comprende: a) una cantidad terapéuticamente efectiva de Alisquireno, o de una sal farmacéuticamente aceptable del mismo, b) una cantidad terapéuticamente efectiva de Amlodipina, o de una sal farmacéuticamente aceptable de la misma,en donde la combinación farmacéutica de dosis oral fija muestra una disolución in vitro del componente (a) del 60 por ciento o menos después de 10 minutos, y del 98 por ciento o menos después de 20 minutos, y un perfil de disolución del componente (b) del 50 por ciento o más después de 20 minutos, y del 70 por ciento o más después de 30 minutos, a un pH de 2, siendo esta combinación farmacéutica de dosis oral fija, bioequivalente o cercana a alcanzar la bioequivalencia, a una combinación de dosis libre de Alisquireno y Amlodipina.
CO11036957A 2008-09-22 2011-03-25 Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina CO6351711A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9894508P 2008-09-22 2008-09-22

Publications (1)

Publication Number Publication Date
CO6351711A2 true CO6351711A2 (es) 2011-12-20

Family

ID=42040192

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11036957A CO6351711A2 (es) 2008-09-22 2011-03-25 Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina

Country Status (21)

Country Link
US (1) US8613949B2 (es)
EP (1) EP2328564A2 (es)
JP (2) JP2012503020A (es)
KR (1) KR20110060942A (es)
CN (1) CN102159195A (es)
AR (1) AR073384A1 (es)
AU (1) AU2009292908B2 (es)
BR (1) BRPI0919350A2 (es)
CA (1) CA2736257A1 (es)
CL (1) CL2011000594A1 (es)
CO (1) CO6351711A2 (es)
EC (1) ECSP11010999A (es)
IL (1) IL211571A0 (es)
JO (1) JO3239B1 (es)
MA (1) MA32719B1 (es)
MX (1) MX2011002988A (es)
MY (1) MY153610A (es)
PE (1) PE20110293A1 (es)
RU (2) RU2014140552A (es)
TW (1) TW201016217A (es)
WO (1) WO2010033954A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2382969A1 (en) * 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN103070863A (zh) * 2011-10-25 2013-05-01 河南省健康伟业生物医药研究股份有限公司 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032954A1 (en) * 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
HU226642B1 (en) 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NZ536555A (en) * 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
DE10223282B3 (de) 2002-05-24 2004-02-05 Orga Kartensysteme Gmbh Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst
FR2853904B1 (fr) 2003-04-15 2007-11-16 Air Liquide Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
US20080161321A1 (en) * 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
EA013053B1 (ru) 2004-11-05 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Двуслойная таблетка, содержащая телмисартан и амлодипин
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20060116435A1 (en) * 2004-12-01 2006-06-01 Housel Tyler L High strength polyurethane foam
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20080991A1 (es) * 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
CN101594857B (zh) 2006-11-07 2012-10-31 诺瓦提斯公司 阿利吉仑半富马酸盐的晶形

Also Published As

Publication number Publication date
AU2009292908A1 (en) 2010-03-25
EP2328564A2 (en) 2011-06-08
US20110165240A1 (en) 2011-07-07
RU2014140552A (ru) 2015-06-20
AR073384A1 (es) 2010-11-03
PE20110293A1 (es) 2011-05-17
JO3239B1 (ar) 2018-03-08
JP2015091830A (ja) 2015-05-14
ECSP11010999A (es) 2011-06-30
RU2011115712A (ru) 2012-10-27
CN102159195A (zh) 2011-08-17
WO2010033954A3 (en) 2010-10-21
IL211571A0 (en) 2011-05-31
CA2736257A1 (en) 2010-03-25
CL2011000594A1 (es) 2011-08-05
KR20110060942A (ko) 2011-06-08
AU2009292908B2 (en) 2012-07-26
BRPI0919350A2 (pt) 2015-12-29
JP2012503020A (ja) 2012-02-02
US8613949B2 (en) 2013-12-24
TW201016217A (en) 2010-05-01
MX2011002988A (es) 2011-04-11
MY153610A (en) 2015-02-27
WO2010033954A2 (en) 2010-03-25
MA32719B1 (fr) 2011-10-02

Similar Documents

Publication Publication Date Title
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
CY1119886T1 (el) Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
CY1112643T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
WO2009088414A3 (en) Oral pharmaceutical dosage forms
ATE458486T1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
BRPI0916877A2 (pt) composição farmacêutica e administração da mesma
CR20110110A (es) Composicion farmaceutica
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
CY1106741T1 (el) Επικαλυμμενα μινι-δισκια παρατεταμενης αποδεσμευσης υδροχλωρικης βενλαφαξινης
CL2007002921A1 (es) Forma solida de dosificacion farmaceutica de administracion oral, que comprende una forma cristalina o amorfa de un compuesto microincluido en un polimero ionico insoluble en agua en proporcion 5:1 a 1:5; y metodo de preparacion.
DE602007011913D1 (de) Pharmazeutische kombination mit 3- (3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
EA201170512A1 (ru) Композиция для перорального введения
CY1114933T1 (el) Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
CY1114791T1 (el) Πιμοβενδανη για χρηση στη θεραπεια της υπερτροφικης μυοκαρδιοπαθειας σε γατες
CO6351711A2 (es) Combinacion de dosis fija en la forma de una tableta de dos copas o de una sola capa de alisquireno y amlodipina
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
CY1113140T1 (el) Στερεα μορφη δοσης απο του στοματος, που περιεχει τον αντιαιμοπεταλιακο παραγοντα κλοπιδογρελη, και μεθοδος για την παρασκευη αυτης
AR067351A1 (es) Combinacion de picotamida con nafronil
AR075058A1 (es) Composicion farmaceutica oral para uso en enfermedades respiratorias y proceso de fabricacion
AR067502A1 (es) Pelets de administracion oral y liberacion retardada de clorhidrato de duloxetina

Legal Events

Date Code Title Description
FC Application refused